SCHEMBL16185137

SCHEMBL16185137

CCOc1cc(-c2cccc(F)c2)cc2c(NC)nc(-c3cnccn3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 6/20 0.46
▸ CHRNA7 P36544 2/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ KIT P10721 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ FFAR1 O14842 1/20 0.36
▸ PDGFRB P09619 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ TGFBR1 P36897 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ GRIN1 Q05586 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ LIMK1 P53667 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ CCNT1 O60563 1/20 0.34
▸ CCNA2 P20248 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK9 P50750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185168 0.91 CHRNA7 (0.37) GRM5CHRNA7KITLMNAMAPT
SCHEMBL16184183 0.91 KIT (0.41) GRM5MAP4K4KITPDGFRBPDGFRA
SCHEMBL14474202 0.91 CHRNA7 (0.45) GRM5CHRNA7KITLMNAMAPT
SCHEMBL16185134 0.89 FFAR1 (0.47) GRM5MAP4K4LMNAFFAR1MAPK14
SCHEMBL16184848 0.89 GRM5 (0.48) GRM5MAP4K4LMNAMAPTABCG2
SCHEMBL16184361 0.87 MAP4K4 (0.42) GRM5MAP4K4WNT1TGFBR1ABCG2
SCHEMBL14474191 0.87 GRM5 (0.44) GRM5CHRNA7MAP4K4KITLMNA
SCHEMBL16185138 0.86 GRM5 (0.48) GRM5CHRNA7MAP4K4KITLMNA
SCHEMBL16185157 0.86 CHRNA7 (0.39) GRM5CHRNA7KITLMNAMAPT
SCHEMBL14474684 0.86 CHRNA7 (0.39) GRM5CHRNA7LMNAMAPTLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB GRM5 37/4885CHRNA7 349/4885MAP4K4 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback